Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Beacon Pharmaceutical Limited, The Bower 4 Roundwood Avenue, Stockley Park, Heathrow, United Kingdom, UB11 1AF
Pharmacotherapeutic group: Gelatin agents
ATC code: B05AA06
Volplex is a colloidal plasma substitute. When used in the treatment of hypovolaemia Volplex produces significant increases in blood volume, cardiac output, stroke volume, blood pressure, urinary output and oxygen delivery.
Volplex promotes osmotic diuresis, thereby helping to protect the kidneys from the adverse effects of hypovolaemia.
The half-life of Volplex is about 4 hours, with the majority of the dose administered being eliminated by renal excretion within 24 hours.
There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the SmPC.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
